News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Alltracel Pharmaceuticals Plc Announces M-doc(TM) Co-Brand Partnership Agreement With 3M


10/19/2005 5:09:53 PM

PARIS, and DUBLIN, Ireland, Feb. 3 /PRNewswire-FirstCall/ -- Alltracel Pharmaceuticals Plc., (AIM: AP.L), the biopharmaceutical R&D company specializing in medical devices and compounds and owner of the stops-bleeding m-doc(TM) first-aid ingredient brand and SEAL-ON(TM) the consumer first-aid brand featuring stops-bleeding as standard, is pleased to announce a material supply, technology transfer and co-brand partnership program with the Health Care division of 3M , the global diversified technology company. The agreement, effective February 01, will allow 3M to launch its first three stops bleeding products featuring Alltracel's m-doc(TM) first-aid ingredient brand inside 3M 's NEXCARE(TM) first aid brand name in 28 countries in Europe and the Middle East.

3M will initially launch m-doc(TM) co-branded plasters/bandages, followed by nasal sponges and wound spray products, under the NEXCARE(TM) first aid brand umbrella, with shipments commencing this quarter, Q1 2004.

Donal O'Brien Alltracel's Chief Operating Officer (COO) commented:

"We are particularly delighted that 3M, a corporation of recognised global stature and enviable reputation for innovation in the healthcare markets and other sectors, is the latest company to join the m-doc(TM) co-brand partnership program in Europe.

"As well as the significant vote of confidence in the m-doc(TM) technology platform, the 3M agreement is significant from an ongoing recurring revenue perspective and is expected to generate more than half a million euro this first year, on the basis of these three products."

Noel Toolan Alltracel's Chief Marketing Officer said:

The NEXCARE brand endorsement of the m-doc(TM) stops bleeding technology platform is another significant milestone for the m-doc(TM) brand and its progress in becoming a standard in the consumer first aid market. This agreement will mean that the benefit of m-doc(TM) stops bleeding technology will now be available in all European markets in partnership with more than 30 respected consumer brands.

About Alltracel: (http://www.alltracel.com/) Alltracel Pharmaceuticals PLC is an innovative bio-pharmaceutical company specializing in medical devices and compounds, which control bleeding and accelerate the natural healing process efficiently. Headquartered in Dublin, Ireland and with an R&D subsidiary in the Czech Republic, Alltracel was founded in 1996 and listed on London's Alternative Investment Market in July 2001.

m-doc(TM) (Micro Dispersed Oxidized Cellulose; (http://www.m-doc.com/) is the end product of Alltracel's patented process, applied to cotton in the form of raw cellulose and is proven as an effective and efficient haemostatic (blood-stopping) agent in wound care devices. The route-to-market is via licensed trademark and ingredient supply agreements with existing recognized wound care brands. SEAL-ON(TM) (http://www.sealonrange.com/) is the world's first first-aid treatment brand featuring stops bleeding m-doc(TM) as standard. The

SEAL-ON(TM) range features six different product delivery systems -- including sprays, nasal plugs, patches and plasters -- each designed for specific usage occasions and all containing the stops-bleeding m-doc(TM) ingredient brand.

R&D on the core -- polysaccharides manipulation -- technology platform has confirmed significant and exciting potential applications beyond the Wound- care market, primarily in the Dermatological and Nutritional Foods market sectors.

About 3M: 3M (http://www.3m.com/), the globally diversified technology company operates in more than 200 countries focusing on the consumer and office; display and graphics; electronics and telecommunications; safety, security and protection services; health care; industrial and transportation sectors. The healthcare division is 3M's largest business unit and with 2003 revenue of almost $4 billion is in itself one of the world's largest healthcare companies, with a particular reputation for innovation. NEXCARE is 3M's international flagship consumer first-aid brand and is sold in all 3M's major markets.

Alltracel Pharmaceuticals PLC

CONTACT: Dublin: Denise Cronin of Alltracel, +353-1-235-2162, orpress@alltracel.com; or London: Debbie Ardern-Jones, +44-207-269-7110, or NewYork: Tiernan Cavanna, +1-212-850-5600, both of Financial Dynamics, forAlltracel


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES